Aims: To investigate the underlying neurobiology between alcohol use, misuse and dependence and cognitive impairment, particularly Alzheimer's disease (AD). Methods: Review of the literature using searches of Medline, Pubmed, EMBASE, PsycInfo, and meeting abstracts and presentations. Results: The role of alcohol as a risk factor and contributor for cognitive decline associated with AD has received little attention. This is despite the high prevalence of alcohol use, the potential reversibility of a degree of cognitive impairment and the global burden of AD. Until now the focus has largely been on the toxic effects of alcohol, neuronal loss and the role of thiamine. Conclusion: We propose alcohol adds to the cognitive burden seen in dementia through additional mechanisms to neurodegenerative processes or may contribute at various mechanistic points in the genesis and sustenance of AD pathology via neuroinflammation. We describe the common underlying neurobiology in alcohol and AD, and examine ways alcohol likely contributes to neuroinflammation directly via stimulation of Toll-like receptors and indirectly from small bowel changes, hepatic changes, withdrawal and traumatic brain injury to the pathogenesis of AD. Short Summary: Alcohol use, misuse and dependence cause cognitive impairment. We propose alcohol adds to the cognitive burden seen in dementia through additional mechanisms to neurodegenerative processes or may contribute at various mechanistic points in the genesis and sustenance of AD pathology via neuroinflammation.
INTRODUCTION
Alcohol use, misuse and dependence are associated with cognitive impairment. Such impairment is commonly seen during intoxication, however, may be enduring for some in abstinence. Several cohort studies show alcohol consumption beyond moderate amounts increases the risk of dementia (National Institute for Health and Care Excellence 2015). Reduced alcohol consumption was shown to lead to longevity (Khaw et al., 2008 ) and more quality-adjusted life years (Myint et al., 2011) . Those who adopted healthy behaviours, of which one was reduced alcohol consumption, were 3.3 times more likely to age successfully.
A link between alcohol misuse and Alzheimer's disease (AD) has been described. Alcohol dependence was a significant and independent predictor of AD with odds ratio ranging from~3 to 4 depending on the length of alcohol dependence, particularly in those 65-79 years old (Zilkens et al., 2014) . The presence of the apolipoprotein E4 allele, a history of heavy drinking or heavy smoking was each associated with an earlier onset of AD by 2-3 years. Diagnosis of AD occurred nearly 10 years earlier in those with all three risk factors compared with those with none (Harwood et al., 2010) . We will propose here a potential underlying biological mechanism for these consistent epidemiological associations.
The principal cause of a dementia syndrome is AD, which is characterized by aggregation of beta-amyloid (Aβ) and tau with contributory neuroinflammation and cerebrovascular insufficiency. The influence of alcohol on the critical Aβ seen in AD and subsequent neurodegeneration is largely unknown. Here, we review the evidence and propose mechanisms in which Aβ pathology may be driven or contributed to by alcohol, leading to microglial activation, neuroinflammation and ultimately neuronal cell death. This could be directly through chronic alcohol use and withdrawal via stimulation of Toll-like receptors (TLRs) 2 and 4 or indirectly by systemic effects of alcohol through the action of circulatory cytokines, prostaglandins and nitric oxide on the brain. By linking Aβ pathology with such direct and indirect effects of alcohol, we propose important novel mechanistic pathways through which AD and Aβ pathology may be driven or contributed to that needs further exploration for research. This may have wide reaching effects when dealing with alcohol-dependent patients and patients at high risk of AD and their use of alcohol.
Importantly, alcohol misuse is also associated with a number of other disorders, which increase the risk of AD and vascular dementia. These include heart disease, cerebrovascular disease, diabetes mellitus, hypertension, smoking, hyperlipidaemia, hypercholesterolaemia and traumatic brain injury (TBI) (Zilkens et al., 2014) . We know that TBI has been shown to be associated with increased 11 C-PIB (a marker of amyloid deposition) binding in positron emission tomography (PET) studies (Hong et al., 2014; Sharp et al., 2014) . TBI following alcohol use may also contribute to this in an additive fashion. However, neuroinflammation is also heavily implicated in these other disorders, so we focus here on how the inflammatory response to alcohol misuse may be linked with Aβ and AD.
Notably, there are no in vivo studies of Aβ levels [plasma, cerebrospinal fluid (CSF) or PET imaging] in alcoholism in man yet. The few published studies in human post-mortem samples from individuals with alcohol abuse did not find increased neuritic plaques or aggregation of Aβ (Aho et al., 2009) . However, in these studies, the amount and severity of alcohol consumption does not appear to have been particularly severe. One study of CSF markers (tau, Aβ) reported that alcoholism could be differentiated from AD; however, none were nutritionally deficient (Kapaki et al., 2005) . This is important given how critical thiamine is to brain metabolism, and how deficiency can lead to neuronal loss in alcoholism. Hence, the epidemiological evidence relating alcohol use to cognitive impairment and dementia is such that the biological basis of these associations requires further elaboration.
ALCOHOL
Drinking alcohol is a socially accepted behaviour. Many people consume alcohol without experiencing any problems but a growing number of people drink in a harmful manner. Global estimates attribute 5.9% of all deaths, and 5.1% of the global burden of disease to alcohol in one year alone (World Health Organisation, 2014) . Harmful use of alcohol ranks among the top five risk factors for disease, disability and death worldwide, causing more than 200 disease and injury conditions (World Health Organisation, 2014) . Worldwide the prevalence of alcohol use disorders is 4.1%. Exposure to alcohol varies considerably by regions. In established market economies in Western Europe, Eastern Europe and in North America, average volume of drinking is the highest, with the lowest being in the Eastern Mediterranean regions and parts of Southeast Asia including India. Patterns were least detrimental in Western Europe and in the Western Pacific region, such as Japan. The overall exposure by volume is quite high and patterns are relatively detrimental throughout the world (Rehm et al., 2003) .
The impact of alcohol misuse is widespread encompassing alcoholrelated illness and injuries (such as alcohol dependence, liver cirrhosis, cancers, cardiovascular disease, diabetes, injuries and infectious diseases amongst others) with significant social impacts to family, friends and wider community. A dose-response relationship exists between alcohol and many acute and chronic disease outcomes (Rehm et al., 2010) . Alcohol use and driving also increases the risk of being involved in a road traffic accident, and the severity of resulting injuries (World Health Organization, 2015) .
The alcohol-related burden of disease among older adults is an increasing concern due to the rapidly ageing population worldwide. Older adults are more vulnerable to alcohol-related harm from a given volume of alcohol (Moos et al., 2009) as are adolescents (World Health Organisation, 2014) . Alcohol has also been shown to be the leading risk factor for death aged 15-69 (World Health Organisation, 2014) .
In addition, women are more vulnerable to alcohol-related harm for a given amount of alcohol compared to men (Wilsnack et al., 2013) . Alcoholic women experience significant deficits in a wide range of neuropsychological domains compared to non-alcoholic women, and are more sensitive to alcohol-related cognitive damage (Nixon, 1994) , and have a greater risk of alcoholic cardiomyopathy and myopathy compared with men (Urbano-Márquez et al., 1995) .
ALCOHOL RELATED BRAIN DAMAGE
The term 'alcohol related brain damage' (ARBD) incorporates a range of psychoneurological and cognitive conditions that are associated with long-term alcohol misuse and related vitamin deficiencies. At one extreme is Wernicke-Korsakoff syndrome (WKS) and at the other, the more frequent milder and often less obvious subtle dysfunctions of executive and memory processes due to the vulnerability of the frontal lobe and hippocampus to adverse effects of alcohol. Notably, these regions are especially vulnerable to Aβ pathology.
ARBD tends to affect people in their 40s and 50s, with females presenting a decade younger than males (Royal College of Psychiatrists, 2014) . Women may be more sensitive to ARBD (Nixon, 1994) . It has been shown that alcoholic women have greater reductions in the left hippocampal formation and corpus callosum after shorter duration of alcohol consumption compared to men; however, there is limited data to support this (Hommer et al., 1996; Agartz et al., 1999) . It appears that alcohol has a differential effect on the central GABA-benzodiazepine receptors in men and women (LingfordHughes et al., 2000) . Although ARBD may substantially recover within 2-3 months, cognitive impairment continues to improve for 2-3 years when abstinent. There is much evidence to suggest that abstinence leads to a substantial recovery of cognitive deficits in the overwhelming majority of individuals. However, in some, impairments may persist and are usually related to concurrent thiamine deficiency or other complications such as vascular dementia in~25% (Wilson et al., 2012) . Older alcoholics show greater volume deficits compared with age-matched control subjects than younger alcoholics, suggesting that the older brain is more vulnerable to the effects of alcohol (Pfefferbaum et al., 1992) .
ALZHEIMER'S DISEASE
The number of people living with dementia worldwide today is estimated at 44 million, set to almost double by 2030 and triple by 2050. The global per annum cost of dementia was estimated in 2010 at US$604 billion, and this is rising (Prince et al., 2014) . Small reductions in potentially modifiable risk factors (such as alcohol consumption) are therefore likely to have a large impact on the global burden of the disease.
The most common cause of dementia is AD. This fatal neurodegenerative disorder is characterized by progressive cognitive impairment, social, functional impairment and memory loss. There are currently no available treatments to cure or stop progression. Treatments such as acetylcholinesterase inhibitors seem to show a modest benefit at best towards the disease (National Institute for Health and Care Excellence, 2006). Pathological evidence gives rise to the amyloid cascade hypothesis, where the accumulation of Aβ plaques and neurofibrillary tau tangles lead to neurodegeneration in AD. Current research suggests that Aβ peptide is cleaved from the transmembrane amyloid precursor protein (APP) by β and γ secretases. These peptides aggregate and form the main component of the diffuse senile plaques found in the brain tissue of AD patients. This initiates the inflammatory processes, which cause neuronal death leading to the progression of AD (Heneka et al., 2015) .
ALCOHOL AND NEUROINFLAMMATION
There is an emerging body of evidence that there is a link between alcohol and neuroinflammation. Alcohol intoxication, withdrawal and chronic use impacts on the immune system, causing microglial activation, releasing pro-inflammatory cytokines, and this is mediated via TLRs. Alcohol also affects the peripheral immune system, causing both thiamine deficiency and increasing precursors of Aβ in the brain. The effects of short-term, long-term and binge drinking in both pre-clinical and clinical studies are examined later.
Alcohol and microglia
Pre-clinical models show how short-term ethanol impacts on the immune system (Pascual et al., 2015) . Most evidence for a role of neuroinflammation in ARBD comes from pre-clinical studies. Activated microglia have been demonstrated in a mouse model of short-term alcohol dependence (Syapin and Alkana, 1988) . In a rat model of long-term alcohol dependence sufficient to produce physical dependence and mild cognitive deficits, activated microglia have been shown to be present for 14 days after the last alcohol dose (Obernier et al., 2002) .
The hyperglutamatergic state during alcohol withdrawal has also been suggested to be a neuroinflammatory stimulus related to microglial activation (Ward et al., 2009) . Pre-clinical binge models suggest that microglia are partly rather than fully activated during alcohol withdrawal-a non-inflammatory phenotype (Marshall et al., 2013) . Also a single binge ethanol exposure results in a low level of microglial activation; however, a second binge potentiated the microglial response in pre-clinical models (Marshall et al., 2016) .
In clinical studies, although increased numbers of microglia in the brains of alcohol-dependent patients at post-mortem have been seen, it is not clear what kind of inflammatory phenotype has been described (He and Crews, 2008) . Clusters of activated microglia and astrocytes have been described in the thalamus and around the third ventricle in post-mortem specimens from patients with WKS (Kril and Harper 2012) . The classical areas of WKS may not be commonly associated with AD, suggesting a need to think beyond its classical conceptualizations. Microglial activation has been demonstrated in vivo in alcohol-dependent patients with hepatic encephalopathy (Cagnin et al., 2006) and in Wernicke's encephalopathy (Tsukahara et al., 2005) . Alcoholic patients with a history of chronic alcohol dependence uncomplicated by liver cirrhosis and/or nutritional deficiencies showed microgliosis and astrogliosis in postmortem samples (Rubio-Araiz et al., 2016).
Alcohol, cytokines and the peripheral immune system
Alcohol affects both cytokines and the peripheral immune system. Alcohol-induced neuroinflammation includes increased brain levels of pro-inflammatory cytokines interleukin 1 (IL-1) and tumour necrosis factor alpha (TNF-α). Reduced anti-inflammatory cytokine IL-10 have been observed in response to chronic high alcohol administration in short-term pre-clinical models. Notably, these persisted for several days while peripheral circulating plasma cytokines were undetectable, favouring a pro-inflammatory milieu in the brain (Qin et al., 2008) .
In pre-clinical models, the impact of ethanol may have dichotomous effects on the peripheral immune system depending on the concentration-having a suppressive effect at high and stimulatory effect at low concentration (Fernandez-Lizarbe et al., 2008) .
Clinical studies show that serum pro-inflammatory cytokines have been increased in patients with chronic alcoholism (McClain and Cohen, 1989; McClain et al., 1999) . Increased pro-inflammatory and anti-inflammatory cytokines early in abstinence have been described (González-Quintela et al., 2000) , as has increased proinflammatory cytokine production by dendritic cells from alcoholdependent participants. In addition to the pathways above, peripheral inflammation is highly likely due to alcohol-related increase in gut bacteria translocation. These peripheral cytokines are known to affect microglial phenotypes (Wang and Hazell, 2010) .
The effects of alcohol in humans on the peripheral immune system are pertinent given the discovery of functional meningeal lymphatic vessels that line the dura of the central nervous system (CNS) connected to the deep cervical lymph nodes, changing a fundamental assumption of neuroimmunology that the brain was an immune privileged site (Louveau et al., 2015) . This communication is particularly important given the wide ranging effects of alcohol peripherally. Peripheral cytokines are also known to communicate with the CNS via vagal afferents, periventricular macrophages and dedicated transporter systems (Laso et al., 2007) .
Alcohol and TLRs
There is evidence for alcohol-related induction of neuroinflammation via direct and indirect mechanisms. Alcohol has been reported to stimulate TLRs. TLRs are pattern recognition receptors in the innate immune system, predominantly expressed in glial cells and critical in the generation of an immune reaction in response to pathogens. Binding of specific ligands to TLRs results in activation of downstream signalling cascades within immune cells. This ultimately results in a state of 'cellular activation' releasing chemokines and cytokines. TLRs also express the co-stimulatory molecules for pattern recognition needed for protective immune responses alongside efficient clearance of damaged tissues (Tahara et al., 2006) . Downstream signalling may proceed via MyD88-dependent and MyD88-independent pathway, the former is considered more important in microglia. This culminates in the activation of transcription factors, and thereby generation of pro-inflammatory cytokines or free radicals (Keogh and Parker, 2011; Pascual et al., 2015) . CD14 acts as a coreceptor and interacts with TLR4 and TLR2 containing dimeric complexes to transduce activation signals in response to bacterial pathogens. It is shown that exogenous and endogenous TLR ligands activate microglia (Tahara et al., 2006) . This is important given alcohol's effect on TLRs. Alcohol may have a direct effect on TLRs as an upstream driver of inflammation as well as a direct effect on downstream inflammatory process. This may ultimately lead to the aggregation of Aβ and tau especially in vulnerable areas like the hippocampus.
In pre-clinical models short-term alcohol models, alcohol has also been shown to activate TLR4 directly in astrocytes and microglia in vitro (Fernandez-Lizarbe et al., 2009 ). This activation leads to expression of the transcription factor TNF-α and expression of enzymes, which regulate the production of prostaglandins and nitric oxide, cyclooxygenase 2 and inducible nitric oxide synthetase (iNOS) (Vallés et al., 2004) . Inflammatory microglial activation and increase in inflammatory cytokines, nitric oxide and prostaglandins in the brain induced in a rodent model of long-term alcohol dependence were reduced to control levels when TLR4 was eliminated by knockout (Alfonso-Loeches et al., 2010), as were associated cognitive deficits in pre-clinical short-term models (Pascual et al., 2007) . Mice lacking TLR4 and TLR2 receptors were protected against ethanol-induced cytokine and chemokine release, and showed ethanol consumption increases cytokine and chemokine levels in the striatum and serum of wild-type mice, but not in TLR4/TLR2 knockout mice, but the effects on the peripheral immune system were not considered.
Alcohol and thiamine deficiency, APP and BACE-1
Lastly, pre-clinical models of thiamine depletion show early microglial activation with blood-brain barrier disruption in equivalent areas to those affected in human populations (Todd and Butterworth, 1999; Wang and Hazell, 2010) .
In addition to neuroinflammation, alcohol abuse is also commonly associated with thiamine deficiency and notably in transgenic AD mouse models, thiamine deficiency has been shown to exacerbate amyloid plaque pathology (Karuppagounder et al., 2009) . Given how critical thiamine is to brain metabolism, it is not surprising therefore that changes in brain metabolism in AD have been related to changes in thiamine-dependent enzymatic activity. Thiamine deficiency induces chronic mild impairment of oxidative metabolism and promotes selective changes in oxidative stress and inflammation that lead to neuronal loss in specific brain regions. In addition to thiamine deficiency, we also know that mice given alcohol show an increase in the APP and beta-secretase 1 levels compared to controls (Kim et al., 2011) . There is little literature linking alcohol and tau. One study attempted to evaluate CSF markers tau and Aβ to differentiate ARBD and AD; however, the implications remain uncertain (Kapaki et al., 2005) .
Given the importance of neuroinflammation in alcohol, it is necessary to elaborate on where these are in common with those pathways of neuroinflammation in AD to provide focus for further investigation.
NEUROINFLAMMATION IN ALZHEIMER'S DISEASE
There is emerging evidence of the potential role of neuroinflammation not just in the progression of AD but as a potential trigger or accelerating event, with a link between inflammation and amyloid plaque formation. It is known that immune system mediated actions contribute to and drive the pathogenesis of AD (Heppner et al., 2015) . Microglial priming seems to be key to this (Heneka et al., 2014; Perry and Holmes, 2014) .
Microglial priming is seen to lead to a self-perpetuating downstream expression of inflammatory cytokines and chemokines resulting in neurodegeneration and neuronal loss. It is hypothesized that a combination of Aβ driven priming of microglial cells, Aβ peptide accumulation within microglia, systemic and local inflammation, together cause chronic activation and 'burn-out' of microglia (Heppner et al., 2015) . Mice models show transient systemic inflammation superimposed on neurodegenerative disease acutely exacerbates cognitive and motor symptoms of disease and accelerates progression (Cunningham et al., 2009) .
In early AD, it is believed that activated microglia and reactive astrocytes are neuroprotective; however, in the later stages, they fail to clear Aβ leading to neuroinflammation and neurodegeneration (Tahara et al., 2006; Gambuzza et al., 2014) . Activated microglial cells in AD are therefore seen as a 'double-edged sword' (Song et al., 2011) . On the one hand, they protect neurons by taking up and degrading aggregated Aβ, but on the other hand, they degrade them and cause release of pro-inflammatory cytokines, chemokines, reactive oxygen species (ROS) and reactive nitrogen species, which harm synapses and neurons (Wyss-Coray, 2006; Rivest, 2009) . Neuropathological evidence confirms these being found in brains and CSF of AD patients (Akiyama et al., 2000; Landreth and Reed-Geaghan, 2009 ).
TLRs are linked to this process. This is important, given the activation of TLRs by alcohol and an association between TLRs and AD (Fassbender et al., 2004; Jana et al., 2008; Richard et al., 2008; Udan et al., 2008) . Depending on the disease stage, TLRs and coreceptors are activated to induce Aβ uptake or downstream inflammatory processes. Fibrillar Aβ (fAβ) is believed to interact directly with TLR2, TLR4 and CD14 and induce microglial Aβ phagocytosis in the beginning stages, and neuroinflammatory responses in the late stages (Heneka et al., 2015) . Apolipoprotein E, a protein linked to AD susceptibility by genetic studies, may modulate microglial function downstream of TLRs resulting in a pro-inflammatory state (Li et al., 2015) . TREM2, another genetic risk factor for AD, has also been linked with macrophage and microglial function and proinflammatory cytokine release in genome wide association study (Guerreiro et al., 2013; Lambert et al., 2013; Yaghmoor, 2014) . We are not aware anyone has looked at this in alcohol.
In vitro mouse models support this process. Co-administration of Aβ with TLR4 or TLR2 ligand in microglial cultures led to additive release of nitric oxide and TNF-α from microglia (Lotz et al., 2005) . Daily intraventricular injection of lipopolysaccharide for 14 days induced premature fAβ deposits in young mouse models (Sheng et al., 2003) . CD14 and TLR2 and 4 are required for fAβ stimulated microglial activation which together act to bind fAβ and to activate intracellular signalling, with both stimulating NADPH oxidase and forming ROS . Hence, activation of TLR signalling can exacerbate AD by induction of oxidative stress, inflammation and Aβ deposition.
There is evidence that TLRs are involved in the microglial response to Aβ as inhibition of TLR4 or TLR2 also prevented fAβ-induced nitrite, IL-6 and TNF-αproduction (Walter et al., 2007; Jana et al., 2008; Udan et al., 2008; Reed-Geaghan et al., 2009) . Furthermore, a polymorphism in the TLR4 gene results in a blunted signalling response and is correlated with a 2.7-fold reduction in risk for late onset AD (Minoretti et al., 2006) .
Conversely, some studies conclude enhanced TLR4 signalling promotes clearance of Aβ. Mice models homozygous for destructive mutation of TLR4 had increases in Aβ on immunocytochemistry compared with wild-type models TLR4 (Tahara et al., 2006) . Deficiency in an AD mouse model increased Aβ42 in the brain and exacerbated cognitive impairments in one model (Richard et al., 2008) . Inhibition of TLR2 in microglia reduced the detrimental effect of inflammatory activation while enhancing the beneficial effect of Aβ clearance (Liu et al., 2011) . This supports the hypothesis that TLR4 and TLR2 signalling in the early stages of AD pathogenesis may be neuroprotective, but in the late stages neurotoxic (Song et al., 2011) .
Neuronal loss is a prominent element of AD pathology. In one study, neuronal apoptosis was induced by the addition of conditioned media from Aβ-stimulated monocytes (Combs et al., 2001) . Hippocampal neurons exposed to conditioned media from microglia treated with aggregated Aβ42 resulted in neuronal death, however, media from CD14 or TLR4 knockout microglia treated with Aβ42 was unable to kill neurons in the brain parenchyma (Fassbender et al., 2004; Walter et al., 2007; Landreth and Reed-Geaghan, 2009 ). TLR4-dependent upregulation of cytokines in a transgenic mouse model of AD, namely IL-1β, IL-10, IL-17 and TNF-α in TLR4w AD mice compared with non-AD mice and suggest TLR4 signalling as a new therapeutic target for AD (Jin et al., 2008) .
The role of tau in neuroinflammation is currently uncertain. Alzheimer's neuroinflammation can manifest without neurofibrillary tangles.
LINKING NEUROINFLAMMATION IN ALZHEIMER'S DISEASE AND ALCOHOL MISUSE
Given the above evidence of a role for neuroinflammation in both AD and that alcohol increases neuroinflammation, it appears highly likely that Aβ pathology is influenced by alcohol both directly and indirectly via common pathways (see Figs 1 and 2) .
There is an emerging consensus on the role of the innate immune system in both AD and in the effects of alcohol. As described, both AD and alcohol cause neuroinflammation via the action of TLRs, in particular TLR4 and TLR2. The action of microglial cells are suggested to be key to this process. Downstream inflammatory cascades are activated, and release of certain cytokines and chemokines are thought to lead to neuronal death. Modulation of the effects of Aβ via TLR appears central to this. Alcohol in stimulating TLR4 may modulate this process and a positive feedback loop may be established via TNFα (Kuno et al., 2005) .
Indirect systemic effects of alcohol may lead to microglial activation directly, and contribute to the self-perpetuating cycle of inflammatory processes in the Aβ cascade. This is due to the small bowel changes, hepatic changes and withdrawal effects and the resultant circulatory cytokine release and increased endothelial expression of Fig. 1 . Proposed links between alcohol and Aβ cascade in AD through inflammatory processes. Aβ peptide is cleaved from the transmembrane APP by β and γ secretases. There is an increase in production or reduced clearance of Aβ with the likelihood of conversion shown by solid arrows, and less conversion illustrated by dotted arrows. Different forms of Aβ affect microglial cell activation differently, and Aβ fibrils are shown to activate microglial cells, leading to inflammatory cytokines and chemokines release, further both re-activating microglial cells, and also causing increased aggregation of Aβ towards plaque forms. This self-perpetuating cycle leads to neurodegeneration and cell death. It is suggested that alcohol acts both directly and indirectly on this system. Directly alcohol causes TLR2/4 stimulation and together with fAβ it leads to increased microglial activation, and greater inflammatory cytokines and chemokine release. Indirectly alcohol via small bowel, hepatic and withdrawal effects causes increased circulatory cytokines, in particular TNFα, IL-1β, IL-6 and endothelial expression of prostaglandins and iNOS which cause direct microglial cell activation, and contribute to neuroinflammation by cytokines and chemokines release. The summation of effects results in more neurodegeneration and cell death, greater microglial burn-out, and increased aggregation of Aβ due to a combination of increased inflammatory mediators, and decreased or saturated microglial cells.
prostaglandins, and iNOS. Through the action of circulatory cytokines, prostaglandins and nitric oxide on the brain, this may lead to microglial activation and microglial burn-out further driving Aβ pathology and causing subsequent neuroinflammation and ultimately neuronal cell death. Given this evidence alcohol might be responsible for the induction and perpetuation of AD.
CONCLUSION
The global burden of both alcohol and AD is increasing. Although epidemiological studies reveal alcohol as an important risk factor for AD, the underlying mechanism has not received focus. We have reviewed here how neuroinflammation may be involved and provide a link between Aβ pathology and alcohol misuse. This may be through binge or chronic alcohol use and withdrawal directly stimulating TLR2 and 4 or indirectly by systemic effects of alcohol through the action of circulatory cytokines, prostaglandins and nitric oxide on the brain. Both these routes lead to microglial activation, neuroinflammation and ultimately neuronal cell death, seen in AD.
The mechanisms described herein require appropriate testing. This area of research has received limited attention so far and redressing this would be a valuable contribution to dealing with AD. This may also have wide reaching effects when considering the adverse effects of alcohol misuse in the general population as well as when treating alcohol-dependent patients. Traditionally, the cognitive deficits and brain damage associated with alcohol use has shown some improvement and a degree of reversibility on abstinence from alcohol use. If alcohol dependence and AD share a common mechanistic pathology, then treatment of any alcohol misuse or dependence to support cessation would be an important clinical consideration for those at risk of AD and in the treatment of patients with AD to provide a pivotal disease modifying strategy.
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